$10 Million Funding Supports Children's Cancer Vaccine

CancerVAX, Inc. announced today that it recently launched a funding round of up to $10 million to empower the Utah-based Company to continue working on its breakthrough cancer treatments.

CancerVax CEO Ryan Davies said in a June 14, 2023, press release, “We’re working with a research team at UCLA to help us develop these treatments. We’ve raised $2 million of seed funding thus far and are using the StartEngine platform to raise an additional $10 million to further the development of these novel cancer therapies.”

CancerVAX recently announced that its UCLA research team had made positive progress towards developing a treatment for Ewing sarcoma, a deadly form of cancer.

Ewing sarcoma is an aggressive bone and soft-tissue cancer with limited chances of cure, more prevalent in adolescents and young adults.

Current therapies for Ewing sarcoma have reached a plateau over the last several decades, and there is an urgent need for improved outcomes.

Approaches that target chemotherapy-resistant tumors, especially in metastatic and/or microscopic residual disease, would be revolutionary, wrote CancerVAX on June 12, 2023.